Shakur Y - Search Results

1

Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family.

Shakur Y, Holst LS, Landstrom TR, Movsesian M, Degerman E, Manganiello V. Shakur Y, et al. Prog Nucleic Acid Res Mol Biol. 2001;66:241-77. doi: 10.1016/s0079-6603(00)66031-2. Prog Nucleic Acid Res Mol Biol. 2001. PMID: 11051766 Review. No abstract available.

2

Therapeutic potential of phosphodiesterase inhibitors in parasitic diseases.

Shakur Y, de Koning HP, Ke H, Kambayashi J, Seebeck T. Shakur Y, et al. Handb Exp Pharmacol. 2011;(204):487-510. doi: 10.1007/978-3-642-17969-3_20. Handb Exp Pharmacol. 2011. PMID: 21695653 Review.

3

Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice.

Sun B, Li H, Shakur Y, Hensley J, Hockman S, Kambayashi J, Manganiello VC, Liu Y. Sun B, et al. Among authors: shakur y. Cell Signal. 2007 Aug;19(8):1765-71. doi: 10.1016/j.cellsig.2007.03.012. Epub 2007 Apr 6. Cell Signal. 2007. PMID: 17482796

4

Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart.

Shakur Y, Fong M, Hensley J, Cone J, Movsesian MA, Kambayashi J, Yoshitake M, Liu Y. Shakur Y, et al. Cardiovasc Drugs Ther. 2002 Sep;16(5):417-27. doi: 10.1023/a:1022186402442. Cardiovasc Drugs Ther. 2002. PMID: 12652111

5

Cilostazol as a unique antithrombotic agent.

Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F. Kambayashi J, et al. Among authors: shakur y. Curr Pharm Des. 2003;9(28):2289-302. doi: 10.2174/1381612033453910. Curr Pharm Des. 2003. PMID: 14529391 Review.

6

Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.

Liu Y, Shakur Y, Yoshitake M, Kambayashi Ji J. Liu Y, et al. Among authors: shakur y. Cardiovasc Drug Rev. 2001 Winter;19(4):369-86. doi: 10.1111/j.1527-3466.2001.tb00076.x. Cardiovasc Drug Rev. 2001. PMID: 11830753 Review.

7

Functions of the N-terminal region of cyclic nucleotide phosphodiesterase 3 (PDE 3) isoforms.

Kenan Y, Murata T, Shakur Y, Degerman E, Manganiello VC. Kenan Y, et al. Among authors: shakur y. J Biol Chem. 2000 Apr 21;275(16):12331-8. doi: 10.1074/jbc.275.16.12331. J Biol Chem. 2000. PMID: 10766874

8

Membrane localization of cyclic nucleotide phosphodiesterase 3 (PDE3). Two N-terminal domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulum.

Shakur Y, Takeda K, Kenan Y, Yu ZX, Rena G, Brandt D, Houslay MD, Degerman E, Ferrans VJ, Manganiello VC. Shakur Y, et al. J Biol Chem. 2000 Dec 8;275(49):38749-61. doi: 10.1074/jbc.M001734200. J Biol Chem. 2000. PMID: 10952971

9

Phosphodiesterases as targets for intermittent claudication.

Liu Y, Shakur Y, Kambayashi J. Liu Y, et al. Among authors: shakur y. Handb Exp Pharmacol. 2011;(204):211-36. doi: 10.1007/978-3-642-17969-3_9. Handb Exp Pharmacol. 2011. PMID: 21695642 Review.

10

Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum.

Shakur Y, Wilson M, Pooley L, Lobban M, Griffiths SL, Campbell AM, Beattie J, Daly C, Houslay MD. Shakur Y, et al. Biochem J. 1995 Mar 15;306 ( Pt 3)(Pt 3):801-9. doi: 10.1042/bj3060801. Biochem J. 1995. PMID: 7702577 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results